Literature DB >> 22999271

Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study.

Damien C Weber1, Thomas Zilli, Jean Paul Vallee, Michel Rouzaud, Raymond Miralbell, Luca Cozzi.   

Abstract

PURPOSE: Rectal toxicity is a serious adverse effect in early-stage prostate cancer patients treated with curative radiation therapy (RT). Injecting a spacer between Denonvilliers' fascia increases the distance between the prostate and the anterior rectal wall and may thus decrease the rectal radiation-induced toxicity. We assessed the dosimetric impact of this spacer with advanced delivery RT techniques, including intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT), and intensity modulated proton beam RT (IMPT). METHODS AND MATERIALS: Eight prostate cancer patients were simulated for RT with or without spacer. Plans were computed for IMRT, VMAT, and IMPT using the Eclipse treatment planning system using both computed tomography spacer+ and spacer- data sets. Prostate ± seminal vesicle planning target volume [PTV] and organs at risk (OARs) dose-volume histograms were calculated. The results were analyzed using dose and volume metrics for comparative planning.
RESULTS: Regardless of the radiation technique, spacer injection decreased significantly the rectal dose in the 60- to 70-Gy range. Mean V(70 Gy) and V(60 Gy) with IMRT, VMAT, and IMPT planning were 5.3 ± 3.3%/13.9 ± 10.0%, 3.9 ± 3.2%/9.7 ± 5.7%, and 5.0 ± 3.5%/9.5 ± 4.7% after spacer injection. Before spacer administration, the corresponding values were 9.8 ± 5.4% (P=.012)/24.8 ± 7.8% (P=.012), 10.1 ± 3.0% (P=.002)/17.9 ± 3.9% (P=.003), and 9.7 ± 2.6% (P=.003)/14.7% ± 2.7% (P=.003). Importantly, spacer injection usually improved the PTV coverage for IMRT. With this technique, mean V(70.2 Gy) (P=.07) and V(74.1 Gy) (P=0.03) were 100 ± 0% to 99.8 ± 0.2% and 99.1 ± 1.2% to 95.8 ± 4.6% with and without Spacer, respectively. As a result of spacer injection, bladder doses were usually higher but not significantly so. Only IMPT managed to decrease the rectal dose after spacer injection for all dose levels, generally with no observed increase to the bladder dose.
CONCLUSIONS: Regardless of the radiation technique, a substantial decrease of rectal dose was observed after spacer injection for curative RT to the prostate.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999271     DOI: 10.1016/j.ijrobp.2012.03.028

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.

Authors:  Ruggero Ruggieri; Stefania Naccarato; Pavel Stavrev; Nadejda Stavreva; Sergio Fersino; Niccolò Giaj Levra; Rosario Mazzola; Pietro Mancosu; Marta Scorsetti; Filippo Alongi
Journal:  Br J Radiol       Date:  2015-08-03       Impact factor: 3.039

2.  Current role of spacers for prostate cancer radiotherapy.

Authors:  Michael Pinkawa
Journal:  World J Clin Oncol       Date:  2015-12-10

3.  The rectovaginal septum: visible on magnetic resonance images of women with Mayer-Rokitansky-Küster-Hauser syndrome (Müllerian agenesis).

Authors:  Markus Huebner; Katharina Rall; Sara Yvonne Brucker; Christl Reisenauer; Katja Claudia Siegmann-Luz; John O L DeLancey
Journal:  Int Urogynecol J       Date:  2014-03       Impact factor: 2.894

Review 4.  A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.

Authors:  M E Schutzer; P F Orio; M C Biagioli; D A Asher; H Lomas; D Moghanaki
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-17       Impact factor: 5.554

5.  PEG spacer gel and adaptive planning vs single plan in external prostate radiotherapy--clinical dosimetry evaluation.

Authors:  Vesa-Pekka Heikkilä
Journal:  Br J Radiol       Date:  2015-09-15       Impact factor: 3.039

Review 6.  The role of radioprotective spacers in clinical practice: a review.

Authors:  Qiuying Tang; Feng Zhao; Xiaokai Yu; Lingyun Wu; Zhongjie Lu; Senxiang Yan
Journal:  Quant Imaging Med Surg       Date:  2018-06

7.  Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy.

Authors:  Masahide Saito; Toshihiro Suzuki; Yuya Sugama; Kan Marino; Naoki Sano; Takafumi Komiyama; Shinichi Aoki; Yoshiyasu Maehata; Kazuya Yoshizawa; Kazunari Ashizawa; Hidekazu Suzuki; Koji Ueda; Yosuke Miyasaka; Masayuki Araya; Hiroshi Takahashi; Hiroshi Onishi
Journal:  J Radiat Res       Date:  2020-05-22       Impact factor: 2.724

8.  Hydrogel Spacer Reduces Rectal Dose during Proton Therapy for Prostate Cancer: A Dosimetric Analysis.

Authors:  Praveen Polamraju; Alexander F Bagley; Tyler Williamson; X Ronald Zhu; Steven J Frank
Journal:  Int J Part Ther       Date:  2019-05-01

9.  Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel.

Authors:  Antoni Rucinski; Stephan Brons; Daniel Richter; Gregor Habl; Jürgen Debus; Christoph Bert; Thomas Haberer; Oliver Jäkel
Journal:  Radiat Oncol       Date:  2015-02-27       Impact factor: 3.481

10.  Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study.

Authors:  Filippo Alongi; Luca Cozzi; Stefano Arcangeli; Cristina Iftode; Tiziana Comito; Elisa Villa; Francesca Lobefalo; Pierina Navarria; Giacomo Reggiori; Pietro Mancosu; Elena Clerici; Antonella Fogliata; Stefano Tomatis; Gianluigi Taverna; Pierpaolo Graziotti; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2013-07-08       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.